Stock-Based Compensation

9 Months Ended

Sep. 30, 2019

Share-based Payment Arrangement [Abstract]

The table below summarizes the impact of recording stock-based compensation expense in the Condensed Consolidated Statements of Operations and Comprehensive Loss during the three and nine months ended September 30, 2019 and 2018:



	Three Months Ended September 30,					Nine Months Ended September 30,
	2019		2018			2019		2018
Cost of goods sold	$	234	$	111		$	640	$	614
Operating expenses:
Research and development	393		146			1,056		841
Clinical and regulatory affairs	216		(49		)	589		383
Marketing and sales	1,116		685			2,510		2,505
General and administrative	1,451		632			3,499		4,468
Total operating expenses	3,176		1,414			7,654		8,197
Total	$	3,410	$	1,525		$	8,294	$	8,811